Fibroblast growth factor 23: Friend or foe in uremia?

Journal of Clinical Investigation

Volumn 122, Issue 7, 2012, Pages 2354-2356

  Moe, Orson W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VITAMIN D;

BLOOD VESSEL CALCIFICATION; CARDIOMYOPATHY; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; GENE MUTATION; KIDNEY DYSFUNCTION; MINERAL METABOLISM; NONHUMAN; NOTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; SURVIVAL; UREMIA; VITAMIN BLOOD LEVEL;

ANIMALS; FIBROBLAST GROWTH FACTORS; HYPERPARATHYROIDISM, SECONDARY; MALE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84863550126     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64184     Document Type: Note

References (19)

1. [No authors listed]. Strategies for influencing outcomes in pre-ESRD and ESRD patients: a special conference. 1998. Proceedings. Am J Kidney Dis. 1998;32(6 suppl 4):S1-S193.
2. Bernard C. Introduction a L'etude de la Medecine Experimentale. Paris, France: Éditions Garnier-Flammarion; 1865.
3. D'Apolito M, et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J Clin Invest. 2010;120(1):203-213.
4. European Uremic Toxin (EUTox) Work Group of the ESAO and ERA-EDTA. EUTox Web site. www.uremic-toxins.org. Accessed May 23, 2012.
5. Singh AK. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens. 2010;19(5):420-424.
6. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI). National Kidney Foundation Web site. http://www.kidney.org/ professionals/KDOQI/guidelines-commentaries.cfm. Accessed May 23, 2012.
7. Clinical practice guidelines. Kidney Disease: Improving Global Outcomes (KDIGO) Web site. http://www.kdigo.org/clinical-practice-guidelines/index.php. Accessed May 23, 2012.
8. ADHR-Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26(3):345-348.
9. Shimada T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98(11):6500-6505. (Pubitemid 32488266)
10. Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev. 2012;92(1):131-155.
11. Isakova T. Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens. 2012;21(3):334-340.
12. Faul C, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393-4408.
13. Goetz R, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A. 2010;107(1):407-412.
14. Razzaque MS. Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372. Expert Opin Ther Pat. 2010;20(7):981-985.
15. Hasegawa H, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010;78(10):975-980.
16. Yamazaki Y, et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008;23(9):1509-1518.
17. Shalhoub V, et al. FGF23 neutralization improves chronic kidney disease - associated hyperparathyroidism yet increases mortality. J Clin Invest. 2012;122(7):2543-2553.
18. Zoccali C, et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol. 2011;22(10):1923- 1930.
19. Hu MC, et al. Klotho deficiency and vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011;22(1):124-136.